NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
541 Värmland

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 518 16.2% 171 5.4% 16 0.5% 1 0.0% . . 4 0.1% 2484 77.8% 3194 100.0%
ASCUS 277 31.0% 299 33.5% 73 8.2% 1 0.1% . . 16 1.8% 227 25.4% 893 100.0%
LSIL 142 20.3% 289 41.4% 89 12.8% . . . . 6 0.9% 172 24.6% 698 100.0%
Atypical glandular cells/AGC 7 50.0% 2 14.3% 1 7.1% 2 14.3% . . . . 2 14.3% 14 100.0%
Unclear atypia . . . . . . . . 1 100.0% . . . . 1 100.0%
ASC-H 2 3.5% 20 35.1% 29 50.9% . . 2 3.5% 1 1.8% 3 5.3% 57 100.0%
HSIL 1 0.8% 21 17.8% 84 71.2% 1 0.8% 3 2.5% . . 8 6.8% 118 100.0%
Suspected Adenocarcinom . . . . . . 1 11.1% . . . . 8 88.9% 9 100.0%
Squamous cell cancer 1 16.7% . . 3 50.0% . . 2 33.3% . . . . 6 100.0%
Totalt 948 19.0% 802 16.1% 295 5.9% 6 0.1% 8 0.2% 27 0.5% 2904 58.2% 4990 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M84416